In a recent stock transaction, Hans Hull, the Chief Business Officer of Pliant Therapeutics Inc . (NASDAQ:PLRX), sold 15,936 shares of common stock. The sale, which occurred on January 17, 2025, was part of a nondiscretionary sale plan designed to meet Rule 10b5-1 requirements. The shares were sold at an average price of $11.2011, generating a total of approximately $178,500. The transaction comes as the stock trades near its 52-week low of $10.22, having declined about 13.5% in the past week. Despite recent price weakness, analysts maintain a strong bullish stance on the company, according to InvestingPro data.
Following this transaction, Hull directly owns 211,558 shares of Pliant Therapeutics. Additionally, Hull holds shares indirectly through various trusts, including The Sloger Hull Family Trust and trusts for his minor children, though he disclaims beneficial ownership beyond his pecuniary interest in these securities. The company maintains a strong liquidity position with a current ratio of 10.26, indicating robust short-term financial health. InvestingPro subscribers have access to 10+ additional key insights about Pliant Therapeutics' financial position and market performance.
In other recent news, Pliant Therapeutics has seen several developments. The company announced the appointment of Delphine Imbert, Ph.D., as its new Chief Technical Officer, a move that comes as analysts from firms such as InvestingPro revise their earnings expectations for the company upward. Pliant Therapeutics is also making significant strides in its clinical trials, with its Phase 2/3 BEACON-IPF trial for Bexotegrast advancing positively.
Analyst firms H.C. Wainwright and Stifel have maintained their Buy ratings on Pliant Therapeutics, reflecting their confidence in the ongoing trials. The company also reported positive findings from its INTEGRIS-PSC trial, leading to reaffirmed positive ratings from Piper Sandler and Leerink Partners.
Additionally, Pliant Therapeutics has appointed Gary Palmer, M.D., MBA, as the new Senior Vice President of Medical (TASE:PMCN) Affairs. The company has also updated its corporate bylaws to align with recent changes in Delaware law, enhancing its corporate governance practices. These are recent developments in Pliant Therapeutics' efforts in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.